Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AM7D
- Sponsors Takeda Global Research and Development Center
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Oct 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.